GLP-1 microdosing chart: what is on-label?
A GLP-1 microdosing chart is not in FDA labels. GLP-1s use fixed titration schedules and clinician-set dosing. Here is what labels say.
Key facts
- Answer a few health questions online. A licensed clinician reviews them. If approved, it ships to your door.
- Adults 18 or older. A licensed clinician reviews your health history and decides whether treatment is appropriate for you. Availability depends on the state you live in.
People search for a "glp-1 microdosing chart" hoping to find a simple schedule for fewer side effects. The problem is that FDA approved GLP-1 medicines do not provide a microdosing chart in their prescribing information. This page explains what the labels actually say about starting, titrating, missed doses, and common safety issues, so you can have a clearer conversation with your prescriber. Vitals Vault also offers PocketMD, a free AI health companion for questions based on your own history.
- A GLP-1 microdosing chart is not part of FDA labeled dosing for GLP-1 medicines.
- FDA labels use stepwise titration schedules, not personalized microdoses.
- Changing dose timing or amount can raise side effects and reduce benefit.
- If you cannot tolerate titration, ask your prescriber about label options.
GLP-1 microdosing chart: what is on-label?
What people mean by microdosing
Online, microdosing usually means taking smaller than labeled doses or splitting doses to reduce nausea or other side effects. That approach is not described in FDA labels for GLP-1 medicines, so it is not considered on-label dosing.
What labels actually provide
FDA labels provide starting doses and a stepwise titration schedule, plus instructions for missed doses and key warnings. These schedules are designed to improve tolerability while reaching doses studied in clinical trials.
Why this matters
Using a nonstandard schedule can change side effect risk and may affect how well the medication works. If you are struggling, the safest next step is to talk with the clinician who prescribed it rather than trying to build your own chart.
What FDA labels show instead
| Medication (FDA approved product) | What the label includes | Where to find it |
|---|---|---|
| Wegovy (semaglutide) | A stepwise dose escalation schedule and instructions for missed doses | FDA prescribing information |
| Ozempic (semaglutide) | Starting dose, dose escalation, and missed dose instructions | FDA prescribing information |
| Zepbound (tirzepatide) | Starting dose, dose escalation schedule, and missed dose instructions | FDA prescribing information |
| Mounjaro (tirzepatide) | Starting dose, dose escalation schedule, and missed dose instructions | FDA prescribing information |
Why titration exists
GLP-1 and GIP GLP-1 medicines commonly cause gastrointestinal side effects, especially when you first start or increase the dose. Labels use gradual titration to help your body adjust while aiming for doses studied for safety and effectiveness.
Missed dose rules are product-specific
Each FDA approved product has its own missed dose instructions, including timing cutoffs and when to resume the regular schedule. Because these details differ by product, the safest approach is to follow your specific label and your prescriber’s guidance.
Microdosing can blur monitoring
If you take smaller or irregular doses than the label schedule, it can be harder to interpret side effects, appetite changes, and lab trends over time. Your clinician may also have less evidence to guide next steps because trials follow labeled schedules.
Side effects that drive microdosing searches
Common label listed side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. If symptoms are severe, persistent, or you cannot keep fluids down, contact your prescriber promptly because dehydration can worsen kidney problems.
Serious risks to know
GLP-1 medicines have important warnings that can require urgent evaluation, including possible pancreatitis, gallbladder disease, and kidney problems, and they carry a boxed warning about risk of thyroid C-cell tumors in rodents. You should review these risks with your prescriber before changing how you take the medication.
When to talk to a clinician
Severe stomach symptoms
Contact your clinician if vomiting is persistent, you cannot keep fluids down, or you have signs of dehydration. These issues can require a change in plan and may increase the risk of kidney problems.
Severe belly pain
Get medical advice urgently for severe abdominal pain that does not go away, with or without vomiting. FDA labels warn about pancreatitis and gallbladder problems, which need prompt evaluation.
Symptoms of low blood sugar
If you use insulin or a sulfonylurea, ask your clinician about hypoglycemia risk and monitoring. Labels note that combining GLP-1 medicines with insulin secretagogues or insulin can increase hypoglycemia risk.
History of thyroid cancer syndromes
Tell your clinician if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. These are listed contraindications for semaglutide and tirzepatide weight loss products.
Practical tips for safer dosing conversations
Ask for the label schedule
Request the official titration schedule for your exact product and indication.
Describe side effects clearly
Note when symptoms started, how long they last, and what you can tolerate.
Review other medicines
Ask about interactions and hypoglycemia risk if you use insulin or sulfonylureas.
Do not change injection technique here
Use the product Instructions for Use and your pharmacist’s training for technique.
Track what your clinician tracks
Ask which labs and vitals they monitor for safety and response over time.
Frequently Asked Questions
Is there an FDA approved glp-1 microdosing chart?
No. FDA approved GLP-1 products provide specific starting doses and titration schedules in their prescribing information, not a microdosing chart. If you are not tolerating titration, ask your prescriber what label based options exist.
Why do GLP-1 labels use titration instead of microdosing?
Titration is used to improve tolerability, especially gastrointestinal side effects, while reaching doses studied in clinical trials. Microdosing schedules are not described in FDA labels, so there is less evidence to guide safety and effectiveness.
Can I split a weekly GLP-1 dose into smaller doses?
Dose splitting is not part of FDA labeled instructions for GLP-1 products. Changing dose amount or timing can change side effect risk and may affect results, so discuss any changes with the clinician who prescribed your medication.
What side effects make people look for microdosing charts?
Common label listed side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. If symptoms are severe or you cannot keep fluids down, contact your clinician promptly because dehydration can become serious.
How can PocketMD help with GLP-1 dosing questions?
PocketMD is free to download and can help you organize questions using your own labs and health history, and it tells you when to see a clinician. It is not a doctor and is not for emergencies, and dose decisions stay with your prescriber.